MX2010008370A - Paramixovirus oncoliticos atenuados que codifican citoquinas de aves. - Google Patents

Paramixovirus oncoliticos atenuados que codifican citoquinas de aves.

Info

Publication number
MX2010008370A
MX2010008370A MX2010008370A MX2010008370A MX2010008370A MX 2010008370 A MX2010008370 A MX 2010008370A MX 2010008370 A MX2010008370 A MX 2010008370A MX 2010008370 A MX2010008370 A MX 2010008370A MX 2010008370 A MX2010008370 A MX 2010008370A
Authority
MX
Mexico
Prior art keywords
virus
newcastle disease
oncolytic rna
cytokine
rna newcastle
Prior art date
Application number
MX2010008370A
Other languages
English (en)
Inventor
Rudolf Beier
Florian Puehler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2010008370A publication Critical patent/MX2010008370A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a un virus a ARN oncolítico recombinante de la enfermedad de Newcastle para el tratamiento de una enfermedad proliferativa, que comprende al menos un transgen que codifica una citoquina de aves, en donde el virus a ARN oncolítico recombinante de la enfermedad de Newcastle se puede obtener a partir de un virus a ARN de la enfermedad de Newcastle oncolítico velogénico o mesogénico. La expresión mediada por virus de la citoquina en las células huésped natural conduce a una patogenicidad reducida del virus para especies de aves. Aún más, el genoma del virus puede codificar proteínas de unión, enzimas convertidoras de prodrogas o/y proteasas. La expresión selectiva de estas moléculas en célula tumorales infectadas con virus incrementa el efecto antitumoral del virus.
MX2010008370A 2008-01-29 2009-01-20 Paramixovirus oncoliticos atenuados que codifican citoquinas de aves. MX2010008370A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2433308P 2008-01-29 2008-01-29
EP08001643A EP2085092A1 (en) 2008-01-29 2008-01-29 Attenuated oncolytic paramyxoviruses encoding avian cytokines
PCT/EP2009/000308 WO2009095167A1 (en) 2008-01-29 2009-01-20 Attenuated oncolytic paramyxoviruses encoding avian cytokines

Publications (1)

Publication Number Publication Date
MX2010008370A true MX2010008370A (es) 2010-08-23

Family

ID=39708421

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008370A MX2010008370A (es) 2008-01-29 2009-01-20 Paramixovirus oncoliticos atenuados que codifican citoquinas de aves.

Country Status (22)

Country Link
US (1) US20100092430A1 (es)
EP (2) EP2085092A1 (es)
JP (1) JP2011510638A (es)
KR (1) KR20100113096A (es)
CN (1) CN102099045A (es)
AR (1) AR070272A1 (es)
AU (1) AU2009210301A1 (es)
BR (1) BRPI0906354A2 (es)
CA (1) CA2711571A1 (es)
CL (1) CL2009000190A1 (es)
CO (1) CO6290693A2 (es)
CR (1) CR11616A (es)
DO (1) DOP2010000233A (es)
EA (1) EA201001202A1 (es)
EC (1) ECSP10010375A (es)
IL (1) IL206382A0 (es)
MX (1) MX2010008370A (es)
PA (1) PA8813901A1 (es)
PE (1) PE20091355A1 (es)
TW (1) TW200936159A (es)
WO (1) WO2009095167A1 (es)
ZA (1) ZA201006151B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387242B2 (en) 2005-12-02 2016-07-12 Icahn School Of Medicine At Mount Sinai Chimeric viruses presenting non-native surface proteins and uses thereof
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
US9937196B2 (en) * 2009-06-19 2018-04-10 University Of Maryland, College Park Genomic sequence of avian paramyxovirus type 2 and uses thereof
CN103732236B (zh) * 2011-08-05 2017-09-15 新罗杰公司 用于生产痘苗病毒的方法和组合物
AU2014241843B2 (en) * 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
US10519426B2 (en) 2013-09-03 2019-12-31 Medimmune Limited Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia
KR102407019B1 (ko) 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
GB201505860D0 (en) * 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
CN108362875A (zh) * 2018-01-10 2018-08-03 华南农业大学 一种鉴别新城疫感染与免疫的间接elisa方法
CN111094324B (zh) * 2018-03-14 2023-10-10 武汉博威德生物技术有限公司 一种溶瘤病毒、合成dna序列及其应用
TW202043466A (zh) * 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
MXPA01010393A (es) 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
WO2000067786A1 (en) 1999-05-05 2000-11-16 University Of Maryland PRODUCTION OF NOVEL NEWCASTLE DISEASE VIRUS STRAINS FROM cDNAS AND IMPROVED LIVE ATTENUATED NEWCASTLE DISEASE VACCINES
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
WO2001020989A1 (en) 1999-09-22 2001-03-29 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
AU2481502A (en) 2000-11-02 2002-05-15 Akzo Nobel Nv A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
EP1411880B1 (en) 2001-07-11 2018-04-25 University of Miami Recombinant vsv for the treatment of tumor cells
EP1300157B1 (en) 2001-10-04 2005-10-26 Centrum voor Onderzoek in Diergeneeskunde en Agrochemie Attenuated mutant newcastle disease virus strains for in ovo vaccination and their use
US20040072276A1 (en) 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
US20050002897A1 (en) 2003-06-18 2005-01-06 Ulrich Haupts Biological entities and the pharmaceutical or diagnostic use thereof
EA013615B1 (ru) 2004-11-12 2010-06-30 Байер Шеринг Фарма Акциенгезельшафт Рекомбинантный онколитический парамиксовирус и его применение
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株

Also Published As

Publication number Publication date
CR11616A (es) 2010-09-09
PE20091355A1 (es) 2009-10-04
IL206382A0 (en) 2010-12-30
EA201001202A1 (ru) 2011-02-28
US20100092430A1 (en) 2010-04-15
BRPI0906354A2 (pt) 2019-12-17
ZA201006151B (en) 2012-02-29
ECSP10010375A (es) 2010-08-31
CA2711571A1 (en) 2009-08-06
CL2009000190A1 (es) 2010-07-19
DOP2010000233A (es) 2010-08-15
EP2237790A1 (en) 2010-10-13
JP2011510638A (ja) 2011-04-07
PA8813901A1 (es) 2009-08-26
AR070272A1 (es) 2010-03-25
TW200936159A (en) 2009-09-01
CN102099045A (zh) 2011-06-15
AU2009210301A1 (en) 2009-08-06
KR20100113096A (ko) 2010-10-20
CO6290693A2 (es) 2011-06-20
EP2085092A1 (en) 2009-08-05
WO2009095167A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
MX2010008370A (es) Paramixovirus oncoliticos atenuados que codifican citoquinas de aves.
NZ591733A (en) Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising an enzyme
PH12017501942A1 (en) Oncolytic adenovirus encoding a b7 protein
WO2008140621A3 (en) Transgenic oncolytic viruses and uses thereof
MY140829A (en) Chimeric adenoviruses for use in cancer treatment
RU2019107976A (ru) Композиция вакцины
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
Matveeva et al. Oncolysis by paramyxoviruses: preclinical and clinical studies
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
ATE533782T1 (de) Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
WO2006136448A3 (en) Attenuated sars and use as a vaccine
WO2011072247A8 (en) Pathogen restriction factors
JP2012515557A5 (es)
MX2022002547A (es) Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma.
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
RU2013102413A (ru) Парапоксвирусные векторы
Zhang et al. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice
CR20210403A (es) Rhabdovirus recombinante que codifica ccl21
TW200801034A (en) Novel sea lice vaccine
JP6386448B2 (ja) ブタインターフェロンアルファ及びブタインターフェロンガンマを同時に発現する組換えアデノウィルス
Takrim et al. Expression, Purification and Immunogenicity Evaluation of Recombinant Fusion Protein (F) from Newcastle Virus in Animal Model
AR110756A1 (es) Uso de bp005 para el control de patógenos de planta
DE602005018021D1 (de) Impfstoffe mit ornithobakterium rhinotracheale-untereinheit

Legal Events

Date Code Title Description
FA Abandonment or withdrawal